Hims & Hers Health, Inc.
Here’s whether Hims & Hers Health, Inc. (HIMS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+4.24% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 22 — oversold; weak 1-year return of -51.0%; 3-month momentum negative (-8.1%). Currently 60.1% off its 52-week high. Score: -5/7.
HIMS is trading below its 200-day MA ($31.05) — a key warning sign the longer-term trend is under pressure. An RSI of 21.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -51.0% compares to +16.5% for SPY (trailed the market by 67.5%). The current 60.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.